| NCT07007312 | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | NOT_YET_RECRUITING | PHASE3 | 2025-09 | 2031-11 | 2031-11 |
| NCT06655246 | A Study of Ziftomenib, an Oral Menin Inhibitor, in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | RECRUITING | PHASE1 | 2025-03-27 | 2028-12 | 2027-12 |
| NCT06001788 | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | RECRUITING | PHASE1 | 2024-02-22 | 2027-08 | 2026-08 |
| NCT06026410 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | RECRUITING | PHASE1 | 2023-10-18 | 2027-04 | 2027-01 |
| NCT05735184 | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | RECRUITING | PHASE1 | 2023-07-18 | 2030-04 | 2030-04 |
| NCT05693090 | Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer | WITHDRAWN | PHASE1 | 2023-02-01 | 2027-07-27 | 2027-07-27 |
| NCT04997902 | Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2021-12-07 | 2025-12 | 2025-12 |
| NCT04865159 | Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies | TERMINATED | PHASE1 | 2021-05-06 | 2023-05-02 | 2023-05-02 |
| NCT04067336 | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | RECRUITING | PHASE1, PHASE2 | 2019-09-12 | 2028-10-16 | 2028-10-16 |
| NCT03719690 | Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy | COMPLETED | PHASE2 | 2019-03-15 | 2023-05-02 | 2023-05-02 |
| NCT03051035 | First-in-Human Study of KO-947 in Non-Hematological Malignancies | TERMINATED | PHASE1 | 2017-04-06 | 2020-06-02 | 2020-06-02 |
| NCT02807272 | Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia | COMPLETED | PHASE2 | 2017-01-10 | 2020-11-30 | 2020-11-30 |
| NCT02779777 | Tipifarnib in Subjects With Myelodysplastic Syndromes | TERMINATED | PHASE2 | 2016-06-01 | 2018-08-28 | 2018-08-28 |
| NCT02464228 | Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy | COMPLETED | PHASE2 | 2016-02-25 | 2021-03-31 | 2021-03-31 |
| NCT02383927 | Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations | COMPLETED | PHASE2 | 2015-05-13 | 2020-12-14 | 2020-12-14 |